- Previous Close
115.08 - Open
114.24 - Bid 114.95 x 800
- Ask 114.94 x 800
- Day's Range
113.79 - 115.16 - 52 Week Range
90.48 - 148.15 - Volume
6,177,024 - Avg. Volume
4,025,346 - Market Cap (intraday)
516.172B - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
38.12 - EPS (TTM)
3.02 - Earnings Date Nov 6, 2024
- Forward Dividend & Yield 1.45 (1.26%)
- Ex-Dividend Date Aug 16, 2024
- 1y Target Est
143.44
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
www.novonordisk.comRecent News: NVO
View More
Related Videos: NVO
Performance Overview: NVO
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVO
View MoreValuation Measures
Market Cap
515.99B
Enterprise Value
515.16B
Trailing P/E
38.24
Forward P/E
28.17
PEG Ratio (5yr expected)
1.73
Price/Sales (ttm)
13.32
Price/Book (mrq)
30.37
Enterprise Value/Revenue
13.48
Enterprise Value/EBITDA
25.98
Financial Highlights
Profitability and Income Statement
Profit Margin
34.84%
Return on Assets (ttm)
22.80%
Return on Equity (ttm)
88.57%
Revenue (ttm)
258B
Net Income Avi to Common (ttm)
89.9B
Diluted EPS (ttm)
3.02
Balance Sheet and Cash Flow
Total Cash (mrq)
62.65B
Total Debt/Equity (mrq)
50.71%
Levered Free Cash Flow (ttm)
54.49B
Research Analysis: NVO
View MoreCompany Insights: NVO
NVO does not have Company Insights
Research Reports: NVO
View MoreMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, playing the long game on commercial turbine engines; making the case for integrated oils despite the headlines; watching where Prudential tilts; and Nike, Novo Nordisk, and Zhejiang Supor.
Novo Nordisk: Disappointing Early Data for Novel Oral Obesity Drug
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice TargetNovo Nordisk: Disappointing Early Data for Novel Oral Obesity Drug
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice TargetMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, new wave of GLP-1 anti-obesity drugs may tilt the scales; US refiners' margins fading but valuations remain high; Boeing machinists union strike is unfortunate Blow; and Moderna, China Suntien Green Energy, and Mastercard.